GeneDx’s Post

Vortioxetine in Alzheimer’s Disease - Effect on Depression + Cognitive performance 🚀 The study retrospectively analysed 46 Alzheimer's disease (AD) patients treated with vortioxetine for 12 months. “Vortioxetine was safe and well tolerated. Patients with AD and MDD receiving vortioxetine showed meaningful improvements in depressive symptoms, cognitive performance, and daily and global functioning over the 12-month treatment period.” Reference: Effectiveness of Vortioxetine Treatment on Depression and Cognitive Functions in Patients with Alzheimer’s Disease: A 12-Month, Retrospective, Observational Study More on Vortioxetine pharmacology 👉 https://lnkd.in/gahWnwMy #vortioxetine #alzheimers #dementia #depression

Please see the link below for the recording of the Expert Panel Q&A: https://lnkd.in/e9hwJW_r Neurologist Dr Amin, clinical geneticist Prof Kutsche and neurodisability paediatrician Dr Tuffrey answer questions from our families. Epilepsy management and diagnosis, prognosis of MICPCH and managing the more common symptoms of CASK-related disorders all feature in our expert Q&A.

Marte Helene Bjørk discusses advances in epilepsy treatment, including new neurostimulation techniques, emerging drugs for severe epilepsy, and the establishment of first-seizure clinics. She also highlights recent restrictions on valproate use due to potential risks and stresses the importance of early diagnosis for better patient outcomes. 🔗 Read more about EAN 2024 here: https://lnkd.in/dV62Xfaq  #EAN24 #Epilepsy #Neurostimulation

Epilepsies has many forms with far too much unknown about the causes and why current medications can be so ineffective for so many for what is the 4th most common neurological disorder. But amazing advocates like Epilepsies Action Network are working hard to collaborate with organizations, physicians, patients and government to change this. So proud to partner with you in #advocacy!

The rare neurodevelopmental condition CDKL5 is characterized by early-onset epilepsy

Brain protein discovery could lead to #memoryloss and #PTSD treatment - @Futurity @TheBrainDriver #tDCS #BrainStimulation #Alzheimer’s #Dementia #Parkinson’s @TheBrainDriver #tDCS #BrainStimulation #HolisticHealth #Naturopathy #ChiropracticCare #FunctionalMedicine #IntegrativeHealth https://lnkd.in/eHsTNC9B

It's #InternationalEpilepsyDay Epilepsy can often be a secondary condition to some leukodystrophies. To find out more, visit our website: https://lnkd.in/eiFE-eNw #alextlc #helptocope #helptohope #leukodystrophy #epilepsy

Today is International #EpilepsyDay, marking an opportunity to raise #epilepsyawareness all around the world. The team at Xenon Pharmaceuticals Inc. is united in our mission to develop new #therapeutics to improve the lives of people living with epilepsy and reduce the #stigma associated with this #neurological condition. Approximately 50 million people worldwide have epilepsy, a condition in which a person experiences repeated #seizures caused by abnormal electrical activity in the brain. Epilepsy is a #neurological disorder that affects both males and females of all races, ethnic backgrounds, and ages. A person with epilepsy may experience reduced access to educational opportunities, a lack of driving privileges, and difficulty entering certain occupations. Learn more about International Epilepsy Day, a joint initiative created by the International Bureau for Epilepsy (IBE) and the International League Against Epilepsy (ILAE) here: https://lnkd.in/gxZ3QKt

Marte Helene Bjørk discusses advances in epilepsy treatment, including new neurostimulation techniques, emerging drugs for severe epilepsy, and the establishment of first-seizure clinics. She also highlights recent restrictions on valproate use due to potential risks and stresses the importance of early diagnosis for better patient outcomes. 🔗 Read more about EAN 2024 here: https://lnkd.in/dzTEGiny #EAN24 #Epilepsy #Neurostimulation

𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐬 𝐂𝐨𝐛𝐞𝐧𝐟𝐲 𝐟𝐨𝐫 𝐒𝐜𝐡𝐢𝐳𝐨𝐩𝐡𝐫𝐞𝐧𝐢𝐚: 𝐀 𝐌𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞 𝐟𝐨𝐫 𝐏𝐮𝐫𝐞𝐓𝐞𝐜𝐡 𝐇𝐞𝐚𝐥𝐭𝐡 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) PureTech Health today announced that KarXT (xanomeline and trospium chloride), developed by PureTech PureTech, has received FDA approval for the treatment of schizophrenia in adults. This approval triggers milestone payments totaling $29 million from Royalty Pharma and Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March 2024. KarXT, now marketed as Cobenfy, combines xanomeline and trospium chloride to address tolerability issues in treating neuropsychiatric conditions. Eric Elenko Eric Elenko, Co-founder and President of PureTech, noted that this approval is a significant milestone in transforming the lives of patients with schizophrenia. This achievement validates PureTech’s innovative model, generating approximately $1.1 billion to date, and supports the advancement of other programs, including LYT-100 for idiopathic pulmonary fibrosis. Bharatt Chowrira Bharatt Chowrira, CEO of PureTech, emphasized the importance of this milestone and the ongoing focus on unmet medical needs in their pipeline. #FDAApproval #Cobenfy #Schizophrenia #PureTechHealth #BiotechInnovation #Neuropsychiatry #KarunaTherapeutics #BristolMyersSquibb #HealthcareInnovation